ArticleBritish dental journal2026
Medication-related osteonecrosis of the jaw in multiple myeloma patients: a case series.
Article in British dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a complication of antiresorptive and anti-angiogenic therapies used in the management of malignancy and can cause significant functional and aesthetic morbidity for patients. Multiple myeloma (MM) is a plasma-cell haematological malignancy frequently associated with osteolytic bone disease. Antiresorptive therapy (ART) reduces skeletal-related events in MM and other malignancies with skeletal involvement but is associated with an increased risk of MRONJ. This paper presents the clinical features and management of four MRONJ cases, ranging from localised exposed bone to severe maxillary and mandibular destruction, in MM patients who presented to the Dublin Dental University Hospital between 2021 and 2023. MRONJ management is challenging due to its refractory nature. As prevention is paramount, dental practitioners play a key role in minimising risk through comprehensive dental assessments and management before, during and after ART. Multidisciplinary collaboration between dental practitioners and oncology teams, alongside timely diagnosis and risk reduction, is essential to improve outcomes and minimise MRONJ-related complications. These cases are contextualised within current evidence on MRONJ in malignancy, focusing on implicated medications, risk factors, prognostic factors and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.